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Prion protein (PrPC) has neuroprotective functions and herein we demonstrate that astrocytes from
PrPC-over-expressing mice are more resistant to induced cell death than wild-type astrocytes. The
Stress-Inducible-Protein 1 (STI1), a PrPC ligand, prevents cell death in both wild-type and PrPC-
over-expressing astrocytes through the activation of protein-kinase-A. Cultured embryonic astro-
cytes and brain extracts from PrPC-over-expressing mice show higher glial ﬁbrillary acidic protein
expression and reduced vimentin and nestin levels when compared to wild-type astrocytes, suggest-
ing faster astrocyte maturation in the former mice. Our data indicate that PrPC levels modulate
astrocyte development, and that PrPC–STI1 interaction contributes to protect against astrocyte
death.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Prions are responsible for transmissible spongiform encepha-
lopathies (TSEs). The mechanism of disease propagation involves
the interaction of prion scrapie (PrPSc) with its cellular isoform,
prion protein (PrPC), and the subsequent abnormal structural con-
version of the latter [1,2]. The massive neurodegeneration present
in these diseases has been associated with the gain of neurotoxic
activity of PrPSc [3,4]. On the other hand, several cellular functions
have been assigned to PrPC suggesting that its loss-of-function may
be an important component for the pathogenesis of prion diseases
[3,5].
PrPC is highly expressed in the brain and plays several functions
during brain development [1,6–8]. A great number of investiga-
tions concentrated in uncovering the neuronal functions of PrPC,
while its role in glial cells has been poorly addressed. PrPC is found
in cell surface, within cytoplasm, and it can also be secreted [9–11].
This protein has been related to a wide range of neuronal functions
[9,11–20]. PrPC regulates neuronal polarization by b1 integrin
activity and shows interaction with ﬁbronectin and cytoskeleton
dynamics [21]. In addition, PrPC acts as a receptor for the lamininc-1 chain and the transmembrane protein neuronal cell adhesion
molecule (NCAM), which mediates neuronal adhesion and neurite
outgrowth [19,20,22]. In vivo studies showed that interactions of
PrPC with laminin c-1 chain or the Stress Inducible Protein 1
(STI1), another PrPC ligand, are involved with memory consolida-
tion [23,24].
In neuron-glia interaction context, it has been shown that glu-
tamate uptake from astrocytes is dependent on PrPC expression,
which may inﬂuence neuronal survival [25]. In addition, PrPC binds
an astroglial Na1/K1-ATPase involved in lactate transport by astro-
cytes [26]. In neuron-astrocyte co-cultures, astrocytes from wild-
type (WT) mice promoted a higher level of neuritogenesis than
astrocytes obtained from PrPC-null animals. Laminin secreted and
deposited at the extracellular matrix by WT astrocytes shows a
ﬁbrillar organization and promotes neurite outgrowth, while lam-
inin secreted from PrPC-null astrocytes has a punctate pattern and
it is less permissive to neuronal differentiation [11]. Moreover,
both PrPC and STI1 are secreted by astrocytes and support neurito-
genesis and neuronal survival [9,11]. Indeed, PrPC expression in
astrocytes is critical for sustaining essential mechanisms required
for neuronal differentiation and survival.
Recently, it has been demonstrated that PrPC protects an astro-
cyte cell line derived from PrPC-null mice from oxidative stress
[27]. We also veriﬁed that STI1 prevents cell death and induces
morphological changes in WT astrocytes, whereas PrPC-null astro-
cytes are not affected by STI1 treatment, indicating a further role of
PrPC also in glial development [5].
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sion in the brain increases astrocyte resistance to cell death. STI1
prevented cell death in both WT and PrPC over-expressing (Tg20)
astrocytes through the protein kinase A (PKA) pathway. We also
demonstrate that astrocytes show increased glial ﬁbrillary acidic
protein (GFAP) expression and mitogen-activated protein kinase
(MAPK)/extracellular signal-regulated kinases 1 and 2 (ERK1/2)
activity, as well as reduced vimentin and nestin expression, sug-
gesting a faster rate of astrocyte maturation in PrPC over-express-
ing mice.
2. Materials and methods
The experimental approach used in the manuscript is detailed
in Fig. 1.
2.1. Animals
Our experiments were performed with a line of PrPC over-
expressing mice (Tg20) originally described by Fischer et al. [28].
Tg20 mice carry a half genomic construct of the mouse a allele
which expresses 5–8 times more PrPC than the WT mice [28].
The transgene was introduced into mice deﬁcient in PrPC expres-
sion (Prnp0/0) that were generated by Bueler et al. [29]. The WT
mice used (Prnp+/+) in the present study were descendants of a
F1 generation mouse produced by interbreeding the original
parental strains (C57/BL/6J and 129/Sv mice) used to generate
Prnp0/0 mice. TheWTmice express the allele a [30]. Tg20mice were
provided by Dr. Charles Weissmann (Scripps Florida, Jupiter, FL,
USA). The Code of Ethics of the EU Directive 2010/63/EU for animal
experiments was strictly followed for all experiments. This study
was approved by the local Animal Care and Use Committee at
the A.C. Camargo Hospital.
2.2. Astrocyte culture
Primary astrocyte cultures were prepared as previously de-
scribed [11] from the cerebral hemispheres of embryonic day 18Fig. 1. Summary of experimental approach. Prnp+/+ and Tg20 astrocytes were submitted
vimentin, phospho-ERK1/2 and total ERK1/2 antibodies were performed in brain extracts
under these conditions.(E18) WT (Prnp+/+) and PrPC over-expressing mice (Tg20). 3  105
astrocytes (10 cm-plate with 10 ml) were grown in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) enriched with 10% fetal calf ser-
um (FCS, Invitrogen-Life Technologies – NY) until conﬂuence.
2.3. Cell death assay
Mouse recombinant STI1 (His6–STI1) and STI1D230–245 (His6–
STI1D230–245) were puriﬁed as described previously [5,9,31]. Re-
combinant STI1 was quantiﬁed for bacterial lipopolisaccharide
(LPS) contamination by the Limulus Amebocyte Lysate test (Camb-
rex), and samples were puriﬁed by detoxi-gel endotoxin removing
gel (DGRG; Thermo Scientiﬁc Pierce) before use [5]. After conﬂu-
ence, primary astrocyte cultures were pre-incubated in serum free
DMEMwith STI1 (0.05, 0.5, 1.0 or 2.0 lM), STI1D230–245 (1.0 lM) or
control buffer consisting of tris-buffered saline (TBS) for 2 h, fol-
lowed by staurosporine (25, 50, or 100 nM) for 16 h. The signaling
pathway inhibitors ERK1/2 inhibitor (UO126), PKA inhibitor
(KT5720), protein kinase C (PKC) inhibitor (chelerythrine chloride,
chel) and phosphatidylinositol 3-kinase (PI3K) inhibitor
(LY294002) (Calbiochem) were added 1 h before incubation with
STI1. The cell cultures were ﬁxed with 4% paraformaldehyde and
stained with propidium iodide (0.5 lg ml1; Sigma). Cell death in-
duced by staurosporine was detected as condensed and pyknotic
proﬁles and the number of pyknotic nuclei was quantiﬁed in 10
microscopic ﬁelds [5].
2.4. Immunoblotting analysis
Cells were cultured until conﬂuence, the culture medium was
changed to DMEMwith 1% FCS, and STI1 (0.5 lM) was added every
day for 5 days. Cells were incubated for an additional 5 days and
lysed as previously described [5]. Western blotting assays were
conducted using rabbit anti-GFAP (1:1000), mouse anti-vimentin
(1:1000), mouse anti-nestin (1:1000) (Chemicon Int.) and rabbit
anti-b-actin (1:200; Sigma) antibodies. Rabbit or mouse pre-im-
mune serums were used as negative controls. The bands obtained
after X-ray ﬁlm exposure to the membranes were analyzed byto cell death and PKA activity assays. Immunoblotting analysis using GFAP, nestin,
and cultured astrocytes from Prnp+/+ and Tg20 mice. The STI1 effect was investigated
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Values represent the ratio between GFAP, vimentin or nestin and
actin for each sample. Values from untreated Prnp+/+ astrocytes
were set as 1.0, and the others are relative to it. E18 brains were
lysed in the same buffer as the astrocytes, and SDS–PAGE and
immunoblotting were performed using the same conditions de-
scribed above.
2.5. Kinase assays
2.5.1. PKA activity
For determination of PKA activity, conﬂuent astrocytes were
preincubated with a phosphodiesterase inhibitor (Calbiochem),
3-isobutyl-1methylxantine (IBMX; Calbiochem) (100 lM) for 1 h
at 37 C and treated with or without PKA inhibitor KT5720
(0.06 lM) for 1 h at 37 C. STI1 and STI1D230–245 (1.0 lM) or for-
skolin (10 lM) (LC Laboratories) were added to the cultures for
20 min at 37 C. The cells were then lysed and the PKA activity
was determined by y-ATP incorporation into a PKA-speciﬁc sub-
strate provided by the appropriate protein kinase assay system
kit (Upstate Biotechnologies). The reactions were performed
according to the manufacturer’s instructions.
2.5.2. ERK1/2 phosphorylation
Phosphorylation assays were conducted using the PhosphoPlus
p44–42 MAPK (Thr202/Tyr204) antibody kit (Cell Signaling)
according to the manufacturer’s instructions. After conﬂuence,
astrocytes were stimulated with STI1 or STI1D230–245 (0.5 lM) for
different incubation periods and lysed in Laemmli buffer. Cell ex-
tracts were subjected to SDS–PAGE, followed by immunoblotting
with anti-phospho-ERK1/2, and anti-total ERK1/2 antibodies. The
bands obtained after X-ray ﬁlm exposure to the membranes were
analyzed by densitometric scanning and quantiﬁed using Scion Im-
age software.
2.5.3. Statistical analyses
The results represent the mean ± S.D. of at least four indepen-
dent experiments conducted in triplicate. Statistical analyses were
performed by ANOVA followed by the Tukey post hoc test. The
phospho-ERK1/2 statistical analyses were conducted using a sin-
gle-mean Student’s t test.
3. Results
3.1. PrPC expression modulates astrocytes survival through interaction
with STI1 via PKA
Prnp+/+ (WT) and Tg20 primary astrocyte cultures show similar
growth in vitro. However, they are more resistant to cell death in-
duced by staurosporine (Fig. 2A), indicating that PrPC over-expres-
sion protects astrocytes from cell death.
The PrPC-ligand STI1 prevented both Prnp+/+ and Tg20 astrocytes
from staurosporine-induced death in a dose-dependent manner
(Fig. 2B). Additionally, STI1D230–245, which lacks the PrPC binding
site, did not promote survival in astrocytes, conﬁrming that the
protection mediated by STI1 depends on its speciﬁc interaction
with PrPC (Fig. 2C). The protective effect of STI1 was abrogated
by a PKA inhibitor (KT5720), whereas PKC (Chel), PI3K
(LY294002) and ERK1/2 (U0126) inhibitors had no effect
(Fig. 2C). STI1 treatment induced similar PKA activation in both
Prnp+/+ and Tg20 astrocytes, indicating that PKA saturation is
achieved even with lower PrPC levels. Similar PKA activation levels
were also observed when either Prnp+/+ or Tg20 astrocytes were
treated with forskolin, an adenylate cyclase activator. The addition
of STI1D230–245 or STI1 plus a PKA inhibitor had no effect on PKAactivity in both types of astrocytes (Fig. 2D). These results indicate
that PrPC levels are directly correlated with resistance to cell death
and suggest the involvement of the PKA pathway in the STI1/PrPC-
dependent protection against astrocyte death.
3.2. PrPC levels modulate GFAP, vimentin and nestin expression during
brain development
Astrocyte differentiation was evaluated by assessing GFAP,
vimentin and nestin expression. GFAP and vimentin are intermedi-
ate ﬁlament proteins whose expression is regulated during astro-
cyte development [32–35]. The expression of nestin, another
intermediate ﬁlament protein and stem cell marker, is down-
regulated during astrocyte maturation [36]. Interestingly, under
basal conditions, Tg20 astrocytes expressed more GFAP (Fig. 3A)
and less vimentin (Fig. 3B) and nestin (Fig. 3C) than WT cells, indi-
cating that Tg20 cells were more differentiated at this embryonic
stage than their WT counterpart.
When WT astrocytes were treated with STI1, GFAP expression
increased (Fig. 3A), while vimentin (Fig. 3B) and nestin (Fig. 3C)
levels decreased. Conversely, no effect on the basal levels of these
proteins was observed when Tg20 astrocytes were treated with
STI1 (Fig. 3A–C). These results conﬁrm the role of STI1 in astrocyte
differentiation and indicate that in cells that overexpress PrPC, dif-
ferentiation was prematurely achieved.
Similarly to primary cultures, brain extracts from the cerebral
cortex, cerebellum and hippocampus of E18 Tg20 embryos showed
higher GFAP expression (Fig. 4A), and lower vimentin (Fig. 4B) and
nestin levels (Fig. 4C) when compared to WT E18 mice. In particu-
lar, GFAP expression was almost threefold higher in Tg20 mouse
embryo cerebellums relative to Prnp+/+, conﬁrming that PrPC is in-
volved in astrocyte differentiation in the developing brain.
3.3. ERK1/2 activity is increased in PrPC over-expressing astrocytes
STI1 is able to induce ERK1/2 activation in astrocytes (Fig. 5A),
while no ERK1/2 activation was observed in Prnp+/+ astrocytes trea-
ted with STI1D230–245 (Fig. 5B), which conﬁrms our previous data
[5] that ERK1/2 activation is mediated by PrPC–STI1 interaction.
Interestingly, Tg20 astrocytes presented at least fourfold higher
ERK1/2 basal activity, when compared to WT cells (Fig. 5B). Con-
versely, STI1 is unable to activate ERK1/2 in Tg20 astrocytes indicat-
ing that the activation of this enzyme should reach a plateau
within these cells.
4. Discussion
The data presented here provide evidence that PrPC over-expres-
sion promotes resistance to cell death, as well as early astrocyte
maturation. In this study, we demonstrated that PrPC over-expres-
sion protects astrocytes from cell death induced by staurosporine,
an alkaloid isolated from the bacterium Streptomyces staurosporeus,
which is known to induce apoptosis in many cell lines through
caspase-3 activation [37–40].
In fact, Tg20 mice are less susceptible to age-related alterations
in locomotor, anxiety-like responses and short-term social recogni-
tion memory [41]. Moreover, the upregulation of PrPC expression
after cerebral ischemia and hypoxia exerts a neuroprotective effect
on injured neural tissue [42]. On the other hand, our group has
demostrated that PrPC-null astrocytes were more sensitive to
staurosporine-induced cell death than WT cells [5]. Recently, it
was demonstrated that the ectopic expression of PrPC protects
PrPC-null astrocyte cell lines from oxidative stress [27]. In addition,
it is known that PrPC-null neurons are more susceptible to stress
conditions, such as serum deprivation [13], Bax expression [14]
Fig. 2. PrPC expression modulates astrocyte survival through interaction with STI1 via the PKA pathway. (A) Dose–response curve of cell death induced by staurosporine
treatment: primary astrocytes were incubated with staurosporine (stauro) (25, 50, or 100 nM) for 16 h. (B) Astrocytes were pre-incubated with STI1 (0.05, 0.5, 1.0 or 2.0 lM)
for 2 h, followed by staurosporine (50 nM) for 16 h. (C) Astrocytes were pre-incubated with STI1 or STI1D230–245, followed by staurosporine for 16 h. Cell cultures were treated
with signaling enzyme inhibitors 1 h before incubation with STI1. (D) Astrocytes were pre-incubated with IBMX and treated with forskolin (forsk), STI1, STI1D230–245 or STI1
plus KT5720 and PKA activity was determined. Prnp+/+ primary astrocytes; Tg20 primary astrocytes. ⁄P < 0.05.
Fig. 3. PrPC over-expression increases GFAP expression and decreases vimentin and
nestin levels in vitro. Primary astrocyte cultures were treated daily with STI1 for
5 days and incubated for an additional 5 days. Cells were lysed and Western blot
assays were conducted (left panels) using anti-GFAP (A), anti-vimentin (B), anti-
nestin (C) and anti-b-actin antibodies for loading controls (A–C). The bands
obtained after membrane X-ray ﬁlm exposure were analyzed by densitometric
scanning (right panels). Values represent the ratios between GFAP, vimentin, nestin
or actin for each sample. Prnp+/+ ( ), Tg: Tg20 ( ). ⁄P < 0.05.
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directly related with neuroprotection.In pathological contexts such as in prion diseases, GFAP acts as a
key player in cytoarchitectural changes from reactive astrocytosis
that is accompanied by an increase in GFAP expression [44]. In
our study, levels of astrocytic-PrPC seem to determine GFAP,
vimentin and nestin expression patterns, and, consequently, the
astrocyte differentiation proﬁle. It is important to notice that
although Tg20 astrocytes present an increase of GFAP expression,
they remain protoplasmatic (ﬂat) on culture which is a typical
morphology of non-reactive astrocytes. This is consistent with pre-
vious in vitro studies showing lower GFAP levels and higher
vimentin and nestin expression in PrPC-null astrocytes related to
WT cells [5], as well as the fact that PrPC expression is positively
correlated to the differentiation of multipotent neural precursors
[45,46].
ERK1/2 activity and GFAP expression levels were increased,
whereas vimentin and nestin expression decreased in PrPC over-
expressing astrocytes when compared to WT astrocytes. Similarly
to our data, the thyroid hormone induces astrocyte differentiation
with MAPK/ERK activation [47] and an increase in GFAP expression
and decrease of vimentin levels [35,48]. In this context, the activa-
tion of formyl peptide receptor 1 (FPRL1) requires MAPK/ ERK
phosphorylation and triggers an increase in GFAP production in
human U87 astrocytoma cells [49]. On the whole, these data sug-
gest that high MAPK/ ERK activity levels are related to an increase
of GFAP expression and decrease of vimentin and nestin expression
in Tg20 cells, resulting in astrocyte maturation.
The present results show that STI1 promotes astrocyte survival
through the PKA pathway in both Prnp+/+ and Tg20 mice. These re-
sults are in accordance to previous data [5] and indicate the
involvement of the PKA pathway in the protection against sauro-
sporin-induced astrocyte death promoted by STI1 interaction with
PrPC. Staurosporin treatment is known to increase expression of
pro-apoptotic oncogene Bax and reduce Bcl-2 expression [37–40].
However, it is unknown whether these pathways are also affected
by STI1.
Fig. 4. PrPC over-expression modulates GFAP, vimentin and nestin expression levels in vivo. E18 brain extracts from cerebellum, cerebral cortex and hippocampus were lysed
and the proteins were submitted to Western blot assays using anti-GFAP (A), anti-vimentin (B), anti-nestin (C) and anti-b-actin as loading controls (A–C) antibodies (left
panels). The bands obtained after membrane X-ray ﬁlm exposure were analyzed by densitometric scanning (right panels). Values represent the ratios between GFAP,
vimentin, nestin or actin for each sample. Prnp+/+ ( ), Tg: Tg20 ( ) extracts from cerebellum, hippocampus or cerebral cortex. ⁄P < 0.05.
Fig. 5. ERK 1/2 activity is increased in PrPC over-expressing astrocytes. ERK1/2 phosphorylation assays: astrocyte cultures were stimulated with 1.0 lM STI1 (A) or STI1D230–
245 (B) for 0, 0.5, 1, 5 and 10 min. Western blots were performed using anti-phospho-ERK1/2 and anti-total ERK1/2 antibodies. Densitometric analyses of bands obtained after
membrane X-ray ﬁlm exposure are shown in the upper panels. Lower panel values represent the ratios between phospho-ERK1/2 (pERK) and total ERK1/2 (ERK) for each
sample. Prnp+/+ ( ), Tg20 ( ). ⁄P < 0.05.
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crease in GFAP expression and a decrease of vimentin and nestin
expression in WT astrocytes but not in PrPC over-expressing cells.
The high PrPC concentration in Tg20 astrocytes could be responsi-
ble for the increased ERK1/2 basal activity and prevents STI1 ef-
fects upon the expression of cytoskeleton proteins. Indeed, Tg20
astrocytes already show higher GFAP expression and lower vimen-
tin and nestin expression in relation to WT astrocytes before STI1-
treatment, suggesting that PrPC over-expression in astrocytes does
accelerate cell maturation independent of STI1-treatment. PrPC has
multiple ligands [7] and the high PrPC levels in Tg20 astrocytes
could facilitate the association of this protein with other partners
besides STI1, to promote astrocyte maturation.In accordance to our studies, it is interesting to note that PrPC-
null astrocytes were more sensitive [5] and Tg20 more resistant
to staurosporine-induced cell death than WT cells (present data),
which suggests that that PrPC is a key element in the promotion
of astrocyte survival. Furthermore, we have demonstrated that
PrPC is a response mediator for STI1 in astrocyte survival and a rel-
evant factor in the modulation of GFAP/vimentin/nestin expres-
sion, which are involved in astrocyte differentiation.
The present study complements previous studies [5] and sug-
gests that high PrPC levels increase resistance to glial death and
promote astrocyte maturation during development. Our group
has demonstrated that PrPC expression in astrocytes during devel-
opment is signiﬁcant for sustaining cell-to-cell interactions, the
C.A. Hartmann et al. / FEBS Letters 587 (2013) 238–244 243organization of the extracellular matrix and the secretion of tro-
phic factors, all of which are essential events for neuronal develop-
ment [11]. In a pathological context, astroglial PrPC is able to
impair the process of neurodegeneration induced by a truncated
prion protein [46,50]. On the other hand, PrPC expression only in
astrocytes is sufﬁcient to cause neuronal damage upon prion infec-
tion [51]. PrPC levels in astrocytes are important not only to mod-
ulate astrocyte development but also in the neuron–glia
interaction and can be associated to prion disease progression.
Therefore, studies regarding PrPC expression associated with its
functions in glial cells are relevant and should be further
investigated.
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